🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Ropivacaine HCL

    Atrium Therapeutics

    Renal Carcinoma

    phase 3 small molecule active

    1 trial

  2. Ropivacaína Altan 2 mg/ml solución inyectable EFG, Adrenalina B. Braun 1 mg/ml Solución Inyectable

    The George Institute

    lumbar arthrodesis

    phase 3 small molecule active

    1 trial

  3. Rosiglitazone Extended Release 2mg

    GlaxoSmithKline

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial

  4. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Hoffmann-La Roche

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  5. Rukobia 600 mg prolonged-release tablets

    ViiV Healthcare Pty Ltd

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

  6. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  7. Ruxolitinib

    Novartis Pharmaceuticals

    Polycythemia Vera

    phase 3 small molecule completed

    1 trial

  8. Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  9. Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  10. Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  11. S-1 therapy

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  12. SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs

    phase 3 small molecule active

    1 trial

  13. SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    2 trials

  14. SAR439774

    Genzyme Europe B.V.

    Hemophilia

    phase 3 small molecule active

    1 trial

  15. SAR439774, SAR439774

    Sanofi-aventis Healthcare Pty Ltd

    Hemophilia

    phase 3 small molecule active

    1 trial

  16. SBRT

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 other active

    3 trials

  17. SDF solution

    The University of Hong Kong

    Dental Caries

    phase 3 other completed

    1 trial

  18. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  19. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial

  20. SER-109

    Seres Therapeutics

    Clostridium Difficile Infection

    phase 3 mab completed

    1 trial

  21. SER-109

    Seres Therapeutics

    Clostridioides Difficile Infection

    phase 3 mab completed

    1 trial

  22. SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE

    The George Institute

    Children under the age of 2 years having surgery lasting at least 2 hours

    phase 3 small molecule active

    1 trial

  23. SGT-003

    Solid Biosciences

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    2 trials

  24. SKY0402

    Pacira Ireland Limited

    Hemorrhoid

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources